Ascendis Pharma A/SASNDNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +26.30% | +5.28% | +339.04% | +269.40% | +40.98% |
| Gross Profit Growth | +35.22% | -5.53% | +416.03% | +310.19% | +36.33% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +2459.58% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.60% | +5.51% | +5.42% | +4.14% | +2.67% |
| Weighted Average Shares Diluted Growth | +5.60% | +5.51% | +11.45% | +4.14% | +2.67% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +363.51% | +62.28% | +124.66% | +344.89% | -5.20% |
| Inventory Growth | +41.49% | +25.95% | +20.77% | +13.78% | +1.96% |
| Asset Growth | +42.87% | +32.27% | +43.47% | +5.57% | +10.39% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +15.28% | +26.64% | +17.82% | +3.17% | +1.73% |
| R&D Expense Growth | -12.75% | +22.52% | -13.76% | -9.06% | -5.45% |
| SG&A Expenses Growth | +23.14% | +43.22% | +42.25% | +63.93% | +69.08% |